Publication:
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study

Issued Date

2020-03-05

Resource Type

Article

ISSN

1471230X

DOI

10.1186/s12876-020-01196-0

Other identifier(s)

2-s2.0-85081200562

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

BMC Gastroenterology. Vol.20, No.1 (2020)

Suggested Citation

Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study. BMC Gastroenterology. Vol.20, No.1 (2020). doi:10.1186/s12876-020-01196-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/53727

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study

Author(s)

Phunchai Charatcharoenwitthaya
 Virasak Wongpaitoon
 Piyawat Komolmit
 Wattana Sukeepaisarnjaroen
 Pisit Tangkijvanich
 Teerha Piratvisuth
 Theeranun Sanpajit
 Chinnavat Sutthivana
 Chalermrat Bunchorntavakul
 Abhasnee Sobhonslidsuk
 Soonthorn Chonprasertsuk
 Chotipong Siripipattanamongkol
 Supatsri Sethasine
 Tawesak Tanwandee

Other Contributor(s)

Chulalongkorn University
 Bhumibol Adulyadej Hospital
 Bumrungrad International Hospital
 Vajira Hospital
 Khon Kaen University
 Faculty of Medicine, Ramathibodi Hospital, Mahidol University
 Thammasat University
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Phramongkutklao College of Medicine
 Prince of Songkla University
 Rajavithi Hospital
 Chiangrai Prachanukroh Hospital

Abstract

© 2020 The Author(s). Background: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6. Methods: We analyzed data from 1021 patients with HCV infection (506 with genotype 1; 16 with genotype 2; 314 with genotype 3; 13 with genotype 4; 166 with genotype 6) who received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12). Results: Overall, SVR12 rate was 98.0% (95% confidence interval [CI], 96.7-98.8%) with daclatasvir plus sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir. SVR12 was achieved by 99.2% (95% CI, 97.9-99.7%) of subjects with genotype 1 infection, 100% (95% CI, 78.5-100%) of those with genotype 2 infection, 96.7% (95% CI, 94.0-98.2%) of those with genotype 3 infection, 90.9% (95% CI, 62.3-98.4%) of those with genotype 4 infection, and 96.7% (95% CI 92.5-98.6%) of those with genotype 6 infection. Patients with advanced liver disease were at risk of treatment failure. Only four patients discontinued treatment before week 4 due to non-hepatic adverse events. Conclusions: In this large cohort of patients with various HCV genotypes managed in the real-world practice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good safety profile, comparable to those observed in clinical trials.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/53727

Collections

Scopus 2020